SAN CARLOS, CA, Clear Labs, a provider of fully automated, next-generation sequencing (NGS) platforms for turnkey diagnostics, announced it has secured $30 million in its Series D financing.
Clear Labs, a provider of fully automated, next-generation sequencing (NGS) platforms for turnkey diagnostics, announced it has secured $30 million in its Series D financing.
The round was led by a strategic investor, along with participation from existing investors, including Counterpoint Global (Morgan Stanley), Felicis, GV, HBM Genomics, Khosla Ventures, Menlo Ventures, Nimble Ventures, Redmile Group, Wing Venture Capital, and funds and accounts advised by T. Rowe Price Associates, Inc.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
